

Toxicological profile	NTIS order No.	CAS No.
1. Di-N-OCTYLPHthalate	PB98-101033	000117-84-0
2. ETHYLENE GLYCOL/	PB98-101108	000107-21-1
PROPYLENE GLYCOL		000057-55-6
3. HEXACHLOROETHANE	PB98-101041	000067-72-1
4. HMX	PB98-101058	002691-41-0
5. HYDRAULIC FLUIDS	PB98-101066	VARIOUS
6. HYDRAZINES	PB98-101025	000302-01-2
1,1-DIMETHYLHYDRAZINE		000057-14-7
1,2-DIMETHYLHYDRAZINE		000540-73-8
DIMETHYLHYDRAZINE		030260-66-3
7. MINERAL-BASED CRANKCASE OIL	PB98-101066	008002-05-9
8. TITANIUM TETRACHLORIDE	PB98-101074	007550-45-0
9. WHITE PHOSPHORUS	PB98-101082	007723-14-0

Dated: December 17, 1997.

Georgi Jones,

*Director, Office of Policy and External Affairs,
Agency for Toxic Substances and Disease
Registry.*

[FR Doc. 97-33508 Filed 12-23-97; 8:45 am]

BILLING CODE 4163-70-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Vaccine Advisory Committee (NVAC), Subcommittee on Future Vaccines, Subcommittee on Immunization Coverage, and Subcommittee on Vaccine Safety: Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory committee meetings.

Name: National Vaccine Advisory Committee (NVAC).

Times and Dates: 9 a.m.-2 p.m., January 12, 1998. 8:30 a.m.-1:15 p.m., January 13, 1998.

Place: Hubert H. Humphrey Building, Room 800, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Notice: In the interest of security, the Department has instituted stringent procedures for entrance to the Hubert H. Humphrey Building by non-government employees. Thus, persons without a government identification card should plan to arrive at the building each day either between 8 and 8:30 a.m. or 12:30 and 1 p.m. so they can be escorted to the meeting. Entrance to the meeting at other times during the day cannot be assured.

Purpose: This committee advises and makes recommendations to the Director of the National Vaccine Program on matters related to the Program responsibilities.

Matters To Be Discussed: Agenda items will include updates on the National Vaccine Program Office (NVPO) activities; the

National Vaccine Plan and NVAC's role in defining priorities for action; unmet needs funding—past, present and future; adult immunization: report of the workgroup; use of non-traditional sites for adult immunization; influenza: a growing need for pandemic preparedness; and a discussion on vaccines for international travel.

In addition, there will be updates on welfare reform and effects on immunization; moving towards a Department of Health and Human Services' vaccine safety action plan; work group on philosophical exemptions—final report; the presidential initiative on immunization registries; global use of critically needed vaccines—strategies to consider. There will be reports from the Subcommittee on Immunization Coverage, Subcommittee on Future Vaccines, and Subcommittee on Vaccine Safety.

Name: Subcommittee on Immunization Coverage.

Time and Date: 2 p.m.-5 p.m., January 12, 1998.

Place: Hubert H. Humphrey Building, Room 423A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee will identify and propose solutions that provide a multifaceted and holistic approach to reducing barriers that result in low immunization coverage for children.

Matters To Be Discussed: This subcommittee will hold a discussion on the review of recommendations from the document, "Strategies to Sustain Immunization Coverage," and the finalization of those recommendations.

Name: Subcommittee on Future Vaccines.

Time and Date: 2 p.m.-5 p.m., January 12, 1998.

Place: Hubert H. Humphrey Building, Room 405A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: The Subcommittee on Future Vaccines will develop policy options and guide national activities which will lead to accelerated development, licensure, and best use of new vaccines in the simplest possible immunization schedules.

Matters To Be Discussed: This subcommittee will hold discussions regarding the continued evaluation of methods to remove barriers to development,

licensure and use of safe and effective new vaccines; combination vaccines, strategic options; and defining future vaccines policy issues for travelers' vaccines.

Name: Subcommittee on Vaccine Safety.

Time and Date: 2 p.m.-5 p.m., January 12, 1998.

Place: Hubert H. Humphrey Building, Room 800, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee will review issues relevant to vaccine safety and adverse reactions to vaccines.

Matters To Be Discussed: This subcommittee will hold discussions regarding its goals; a report from the Task Force on Safer Childhood Vaccines; a project report on benefit-risk communication curriculum development; and agenda items for the next meeting.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Felecia D. Pearson, Committee Management Specialist, NVPO, CDC, 1600 Clifton Road, NE, M/S D50, Atlanta, Georgia 30333, telephone 404/639-4450.

Dated: December 19, 1997.

Carolyn J. Russell,

*Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention (CDC).*

[FR Doc. 97-33666 Filed 12-23-97; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97D-0148]

International Conference on Harmonisation; Guidance on Impurities: Residual Solvents

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is publishing a guidance entitled "Q3C Impurities: